First of all, I think transparency issues are crucial.
The studies referred to by the International Agency for Research on Cancer, IARC, were carried out by independent researchers and not by industry, which is essentially the case in the evaluation [technical difficulties] the studies, which formed the basis of the 2017 report.
In addition, the IARC study—